Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

This publication has 17 references indexed in Scilit:

• Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action
  The Lancet Neurology, 2005
• The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis
  Multiple Sclerosis Journal, 2005
• Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials
  Multiple Sclerosis Journal, 2003
• Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”
  Neurology, 2001
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
  Annals of Neurology, 2001
• Multiple sclerosis: Comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
  Proceedings of the National Academy of Sciences, 2000
• Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
  Journal of Clinical Investigation, 2000
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
  Neurology, 1998
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
  Neurology, 1995
• A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
  New England Journal of Medicine, 1987